Michael Soth
Research Subjects
Michael Soth has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Andreas Kuglstatter
Hoffmann-La Roche, 340 Kingsland Street, Nutley, New Jersey 07110, United States
2 shared publicationsHasim Zecic
2 shared publicationsSandra Frauchiger
Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, California 94304, United States
2 shared publicationsTobias Gabriel
2 shared publications- Aaron E. Bunnell
Department of Rehabilitation Medicine University of Washington Seattle Washington USA
1 shared publication Ada Shao
Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, California 94304, United States
1 shared publication
Latest Publications
- 9 December 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (1) , 345-356
3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models
The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression. We optimized a new inhibitor scaffold, 3-amido-5-cyclopropylpyrrolopyrazines, to a potent example with reasonable kinome selectivity, including selectivity for JAK3 versus JAK1, and good biopharmaceutical properties. Evaluation of this analogue in cellular and in vivo models confirmed functional selectivity for modulation of a JAK3/JAK1-dependent IL-2 stimulated pathway over a JAK1/JAK2/Tyk2-dependent IL-6 stimulated pathway.
- 9 December 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (1) , 345-356
3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models
The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression. We optimized a new inhibitor scaffold, 3-amido-5-cyclopropylpyrrolopyrazines, to a potent example with reasonable kinome selectivity, including selectivity for JAK3 versus JAK1, and good biopharmaceutical properties. Evaluation of this analogue in cellular and in vivo models confirmed functional selectivity for modulation of a JAK3/JAK1-dependent IL-2 stimulated pathway over a JAK1/JAK2/Tyk2-dependent IL-6 stimulated pathway.
- 1 June 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (11) , 3452-3456
3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: Design and development to a highly selective lead
- 1 June 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (11) , 3452-3456
3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: Design and development to a highly selective lead
- 1 January 2009
- Published by The Japan Institute of Heterocyclic Chemistry in HETEROCYCLES
- Vol. 78 (11) , 2811
Synthesis of Heteroaryl-fused Pyrazoles as P38 Kinase Inhibitors
- 1 January 2009
- Published by The Japan Institute of Heterocyclic Chemistry in HETEROCYCLES
- Vol. 78 (11) , 2811
Synthesis of Heteroaryl-fused Pyrazoles as P38 Kinase Inhibitors
- 1 January 2006
- Published by Taylor & Francis in Synthetic Communications
- Vol. 36 (3) , 285-293
Convenient Method for the 3‐Functionalization of Isoindazoles
The C‐3 position of isoindazoles is readily functionalized by metalation with lithium diisopropylamide followed by reaction with a variety of electrophiles.
- 1 January 2006
- Published by Taylor & Francis in Synthetic Communications
- Vol. 36 (3) , 285-293
Convenient Method for the 3‐Functionalization of Isoindazoles
The C‐3 position of isoindazoles is readily functionalized by metalation with lithium diisopropylamide followed by reaction with a variety of electrophiles.